Resectability After Neoadjuvant FOLFIRINOX in Locally Advanced Pancreatic Cancer: A Single-Center Experience

HPB - United Kingdom
doi 10.1016/j.hpb.2016.02.894
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients With FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review

Cancers
Cancer ResearchOncology
2019English

Predictors for Resectability and Survival in Locally Advanced Pancreatic Cancer After Gemcitabine-Based Neoadjuvant Therapy

Pancreatology
EndocrinologyHepatologyMetabolismGastroenterologyDiabetes
2016English

Folfirinox Neoadjuvant Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer - A Retrospective Study

International Journal of Contemporary Medical Research [IJCMR]
2019English

Neoadjuvant FOLFIRINOX for Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Oncologist
Cancer ResearchMedicineOncology
2019English

A Patient-Level Meta-Analysis of FOLFIRINOX for Locally Advanced Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Added Value of Intra-Operative Ultrasound to Determine the Resectability of Locally Advanced Pancreatic Cancer Following FOLFIRINOX Chemotherapy (IMAGE): A Prospective Multicenter Study

HPB
HepatologyGastroenterology
2019English

Final Analysis of a Phase II Study of Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2016English

Systematic Review of FOLFIRINOX in Patients With Locally Unresectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Outcomes With FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer

Journal of Surgical Oncology
MedicineSurgeryOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy